A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker

A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker

Abstract Background Disulfiram and metals inactivate key oncoproteins resulting in anti-neoplastic activity. The goal of this study was to determine the maximum tolerated dose of copper when administered with disulfiram in patients with advanced solid tumors and liver involvement. Methods Disulfiram...

Full description

Bibliographic Details
Main Authors: Kristen C. Kelley, Kenneth F. Grossman, Mary Brittain-Blankenship, Kelli M. Thorne, Wallace L. Akerley, Moises C. Terrazas, Ken M. Kosak, Kenneth M. Boucher, Saundra S. Buys, Kimberly A. McGregor, Theresa L. Werner, Neeraj Agarwal, John R. Weis, Sunil Sharma, John H. Ward, Thomas P. Kennedy, Douglas W. Sborov, Paul J. Shami
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Cancer
Subjects:
Disulfiram
Copper gluconate
S-glutathionylation
Online Access:https://doi.org/10.1186/s12885-021-08242-4

Internet

https://doi.org/10.1186/s12885-021-08242-4

Similar Items